EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multimodal Management of Spinal Cord Hemangioblastomas: A Comprehensive Review

Francisco Alfredo Call-Orellana, Juan Pablo Zuluaga-Garcia, Maria Alejandra Sierra, Mariana Zuluaga-Garcia, Esteban Ramirez-Ferrer, Alejandro Bugarini

Therapeutics · 12.05.2026 · 3 (2) · 12

DOI: 10.3390/therapeutics3020012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutics, online erschienen am 12.05.2026. Verfasst von Francisco Alfredo Call-Orellana und 5 weiteren Autor:innen. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Spinal cord hemangioblastomas are rare, benign, and highly vascular tumors that occur sporadically or in association with von Hippel–Lindau disease. Despite their histological benignity, they often cause significant morbidity due to progressive neurological deficits, syrinx formation, and recurrence in the von Hippel-Lindau population. We performed a comprehensive review of the literature by searching PubMed, EMBASE, and Scopus for studies published in English on spinal cord hemangioblastomas. Eligible studies included original research, case series, and case reports with explicit clinical outcomes or management strategies for pathologically or radiographically confirmed SCHb. Gross total resection is feasible in most cases, leading to durable tumor control and favorable neurological outcomes. Preoperative embolization has been employed selectively to reduce intraoperative bleeding. Radiotherapy, particularly stereotactic radiosurgery, has shown promising local control for surgically inaccessible or recurrent lesions, while conventional external beam approaches provide less consistent results. Anti-angiogenic agents have demonstrated anecdotal benefit, and the HIF-2α inhibitor belzutifan represents the first systemic therapy approved by the FDA for VHL-associated hemangioblastomas. The management of SCHb requires an individualized, multimodal strategy. Microsurgery remains the cornerstone of treatment; radiotherapy and pharmacotherapy are valuable adjuncts for specific clinical scenarios. Further prospective studies are needed to optimize patient selection and integration of these therapies.

Zitieren

APA

Call-Orellana, F. A., Zuluaga-Garcia, J. P., Sierra, M. A., Zuluaga-Garcia, M., Ramirez-Ferrer, E., & Bugarini, A. (2026). Multimodal Management of Spinal Cord Hemangioblastomas: A Comprehensive Review. Therapeutics, 3(2), 12. https://doi.org/10.3390/therapeutics3020012

Vancouver

Call-Orellana FA, Zuluaga-Garcia JP, Sierra MA, Zuluaga-Garcia M, Ramirez-Ferrer E, Bugarini A. Multimodal Management of Spinal Cord Hemangioblastomas: A Comprehensive Review. Therapeutics. 2026;3(2):12. doi:10.3390/therapeutics3020012

BibTeX
@article{CallOrellana2026,
  author = {Call-Orellana, Francisco Alfredo and Zuluaga-Garcia, Juan Pablo and Sierra, Maria Alejandra and Zuluaga-Garcia, Mariana and Ramirez-Ferrer, Esteban and Bugarini, Alejandro},
  title = {Multimodal Management of Spinal Cord Hemangioblastomas: A Comprehensive Review},
  journal = {Therapeutics},
  year = {2026},
  volume = {3},
  number = {2},
  pages = {12},
  doi = {10.3390/therapeutics3020012}
}
Kostenlos starten →